Cassava Sciences is working on bringing its own Alzheimer ... there hangs a dark cloud of a previous US Securities & Exchange Commission (SEC) charge against former members of Cassava’s ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Cassava Sciences, Inc. (SAVA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...